Search research articles
Contact Us
Filters
Showing results (181-190 of 199) with videos related to
Page
of 20
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 16, 2014
Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes
Christine N Duncan, Navneet S Majhail, Ruta Brazauskas, et al.
The New England Journal of Medicine
|
May 7, 2025
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
Jakub Svoboda, Daniel J Landsburg, James Gerson, et al.
Nature
|
December 8, 2022
Author Correction: Decade-long leukaemia remissions with persistence of CD4<sup>+</sup> CAR T cells
J Joseph Melenhorst, Gregory M Chen, Meng Wang, et al.
Nature
|
February 3, 2022
Decade-long leukaemia remissions with persistence of CD4<sup>+</sup> CAR T cells
J Joseph Melenhorst, Gregory M Chen, Meng Wang, et al.
Nature Medicine
|
February 6, 2021
Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A Fraietta, Simon F Lacey, Elena J Orlando, et al.
Nature Medicine
|
May 2, 2018
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A Fraietta, Simon F Lacey, Elena J Orlando, et al.
The Lancet. Haematology
|
March 3, 2019
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
Javier Bolaños-Meade, Ran Reshef, Raphael Fraser, et al.
Nature Medicine
|
January 24, 2024
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
Guido Ghilardi, Joseph A Fraietta, James N Gerson, et al.
The Journal of Clinical Investigation
|
August 16, 2021
BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia
Weimin Kong, Alexander Dimitri, Wenliang Wang, et al.
Nature
|
June 1, 2018
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Joseph A Fraietta, Christopher L Nobles, Morgan A Sammons, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 199) with videos related to
Sort By:
Page
of 20
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 16, 2014
Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes
Christine N Duncan, Navneet S Majhail, Ruta Brazauskas, et al.
The New England Journal of Medicine
|
May 7, 2025
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
Jakub Svoboda, Daniel J Landsburg, James Gerson, et al.
Nature
|
December 8, 2022
Author Correction: Decade-long leukaemia remissions with persistence of CD4<sup>+</sup> CAR T cells
J Joseph Melenhorst, Gregory M Chen, Meng Wang, et al.
Nature
|
February 3, 2022
Decade-long leukaemia remissions with persistence of CD4<sup>+</sup> CAR T cells
J Joseph Melenhorst, Gregory M Chen, Meng Wang, et al.
Nature Medicine
|
February 6, 2021
Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A Fraietta, Simon F Lacey, Elena J Orlando, et al.
Nature Medicine
|
May 2, 2018
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A Fraietta, Simon F Lacey, Elena J Orlando, et al.
The Lancet. Haematology
|
March 3, 2019
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
Javier Bolaños-Meade, Ran Reshef, Raphael Fraser, et al.
Nature Medicine
|
January 24, 2024
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
Guido Ghilardi, Joseph A Fraietta, James N Gerson, et al.
The Journal of Clinical Investigation
|
August 16, 2021
BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia
Weimin Kong, Alexander Dimitri, Wenliang Wang, et al.
Nature
|
June 1, 2018
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Joseph A Fraietta, Christopher L Nobles, Morgan A Sammons, et al.
Page
of 20